Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-892216 in COVID-19
NCT06928051Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of S-892216 in coronavirus disease 2019 (COVID-19), sponsored by Shionogi & Co., Ltd.. Started Jun 2025; status: completed.
02
Drugs
S-892216
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06928051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928051.